Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Annovis Bio Inc
(NY:
ANVS
)
10.47
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Annovis Bio Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
July 24, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members
July 23, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease
July 19, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
July 17, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
July 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
July 09, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast
July 02, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease
June 28, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap
June 27, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
June 26, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate
June 25, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
June 18, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
June 11, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’
June 10, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
June 05, 2024
Via
Investor Brand Network
Annovis Announces New Publication in a Peer-Reviewed Journal
May 21, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
May 17, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
May 16, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
May 16, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
May 13, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
May 09, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
May 06, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
April 29, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
April 02, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
November 02, 2023
From
Annovis Bio
Via
Business Wire
Annovis Bio Announces Pricing of $7.5 Million Public Offering
October 31, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Announces Launch of Proposed Public Offering
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
October 24, 2023
From
Annovis Bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.